Subscribe
Subscribe
Picture of BioVox

BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is powered by Biovia: the health innovation cluster for Flanders.
Picture of BioVox

BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is powered by Biovia: the health innovation cluster for Flanders.

Battling antibiotic resistance: are we ready for a bacteriophage revival?

The discovery of antibiotics fundamentally changed healthcare in the 20th century. Deadly infections suddenly became treatable and millions of lives were saved. But excessive antibiotic use in both healthcare and agriculture has allowed some microbes to become resistant. Resistance has even been reported to last resort treatments, like colistin, in the past few years. With classic antibiotics failing, will trivial infections become deadly again or will we manage to find new solutions? In this two-part series, we will look into some of the fundamentally different therapeutics that are being developed as alternatives to traditional antibiotics. In this second installment, we highlight bacteriophages: are they finally ready to take center stage, nearly 100 years after being discovered?

Women in STEM: fixing the leaky pipeline

The lack of women in STEM is a complex problem, including a loss of girls and women at all levels of a research career – a phenomenon often referred to as the “leaky pipeline” of STEM. Let’s look at why some of these leaks have formed and what we can do to fix them!

Orphan CNS diseases receive attention with new Minoryx site in Belgium

The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and orphan diseases. Co-founder and CEO Marc Martinell spoke to BioVox about his personal reasons for founding the company and why Belgium is such an attractive location to start-ups in the medical sector.

Microbiome linked to depression in a groundbreaking Benelux study

The microbiome had been at the forefront of a lot of research and news in the past few years. Now, a new study published in Nature Microbiology has linked specific microbiome changes with depression and quality of life. The largest of its kind to-date, the research was made possible by over 2000 participants from the Flemish Gut Flora Project and the Dutch LifeLines DEEP project. The results may lead to novel therapies for people suffering from this debilitating mental illness.

From scientist to entrepreneur: how a Belgian chromatography company came to be

AuXin Surgery Announces the Launch of its new CADISS System for Selective Dissection in Surgery

Louvain-la-Neuve, Belgium, 7 February 2019 – AuXin Surgery, a medical device company, announces that it has obtained CE Class III certification for its novel CADISS® System for the surgery of chronic otitis and epidural fibrosis.

Inari’s agricultural revolution hits Europe with a new site in Ghent

Pharmafluidics’ new product launch steers ‘on-a-chip’ separations of complex biological samples to new heights

PharmaFluidics NV is a game-changing innovator in the field of analytical chromatography. The company has devised a fundamentally new way of performing separations by creating nano-LC columns on a silicon chip. Their µPACTM columns enable a robust and highly reproducible detection of more molecules from complex biological samples such as biopsies, proteome digests, culture media or bio-pharmaceutical actives. Building upon their groundbreaking micro Pillar Array technology, a new trapping column was launched today, further improving analytical capabilities and throughput time of analyses with µPACTM columns.

Biocartis raises EUR 55.50 million

New laser-based medical device revolutionizes cardiovascular disease diagnosis

Avoiding the pitfalls of clinical development as a biotech

argenx signs billion-dollar deal with Janssen

Battling antibiotic resistance: a new protein powered solution

IPBES to Launch Global Assessment Report on Biodiversity and Ecosystem Services

19 November 2018 - Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES) to Launch First Global Assessment Report on Biodiversity and Ecosystem Services Since 2005

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle

14 Nov 2018 - Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of the Phase III Estelle® study in the US and Canada. Estelle® is Mithra’s novel combined oral contraceptive (COC), containing 15 mg Estetrol (E4)/ 3 mg drospirenone (DRSP). Top line data remain on track to be reported in Q1 2019.